• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by DexCom Inc.

    5/2/25 4:15:51 PM ET
    $DXCM
    Medical/Dental Instruments
    Health Care
    Get the next $DXCM alert in real time by email
    DEFA14A 1 dxcm-defa14a2025.htm DEFA14A Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934
    (Amendment No.     )

    Filed by the Registrant  ý
    Filed by a party other than the Registrant  ☐

    Check the appropriate box:
    ☐
    Preliminary Proxy Statement
    ☐
    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐
    Definitive Proxy Statement
    ý
    Definitive Additional Materials
    ☐
    Soliciting Material under §240.14a-12
    dexcom-logoxgreenxrgb.jpg
    DexCom, Inc.
    (Name of Registrant as Specified In Its Charter)
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):
    ý
    No fee required
    ☐
    Fee paid previously with preliminary materials
    ☐
    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11



    SUPPLEMENTAL INFORMATION TO THE PROXY STATEMENT FOR THE
    DEXCOM, INC.
    2025 ANNUAL MEETING OF SHAREHOLDERS
    TO BE HELD ON THURSDAY, MAY 8, 2025

    This Supplemental Information to the Proxy Statement, dated May 2, 2025 (this “Supplement”), supplements the Definitive Proxy Statement of DexCom, Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) on March 27, 2025 (the Proxy Statement), relating to the 2025 Annual Meeting of Shareholders of the Company (the “Annual Meeting”) to be held on Thursday, May 8, 2025 at 2:00 p.m. Pacific Time, exclusively online via webcast at www.proxydocs.com/DXCM.
    This Supplement is being filed with the SEC and is being made available to the stockholders of the Company on or about May 2, 2025. Except as described in this Supplement, the information provided in the Proxy Statement continues to apply. To the extent the information in this Supplement differs from or updates information in the Proxy Statement, our stockholders should rely on the information contained in this Supplement. The Proxy Statement contains important additional information. This Supplement should only be read in conjunction with the Proxy Statement.
    As described in our Current Report on Form 8-K filed with the SEC on May 2, 2025, Karen Dahut, a director of the Company, resigned from the Board of Directors of the Company (the “Board”) and all committees thereof effective May 8, 2025. Ms. Dahut’s resignation was not the result of any disagreement between Ms. Dahut and the Company, its management, the Board or any committee thereof, or with respect to any matter relating to the Company’s operations, policies or practices.
    Ms. Dahut’s term as a director was scheduled to expire at the Annual Meeting. As a result of her resignation, Ms. Dahut is no longer a director nominee for election at the Annual Meeting.
    All nominees, other than Ms. Dahut due to her resignation, named in the Proxy Statement continue to stand for re-election at the Annual Meeting, and the form of proxy card included with the Proxy Statement remains valid. However, any votes that are submitted for Ms. Dahut will be disregarded. If you have already returned your proxy card or provided voting instructions, you do not need to take any action unless you wish to change your vote by submitting a new proxy card or voting instructions, and your shares will be voted as specified therein, other than votes with respect to Ms. Dahut. If you have not yet returned your proxy card or submitted your voting instructions, please complete and return the proxy card or submit voting instructions, disregarding Ms. Dahut’s name as nominee for election as a director.
    None of the other agenda items presented in the Proxy Statement are affected by this Supplement. The shares represented by proxy cards returned or voting instructions submitted before the Annual Meeting will be voted with respect to all other matters properly brought before the Annual Meeting as instructed on the proxy card or pursuant to the voting instructions.
    ***

    Get the next $DXCM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $DXCM

    DatePrice TargetRatingAnalyst
    6/16/2025$102.00Buy
    Truist
    5/30/2025$104.00Buy
    Goldman
    4/10/2025$85.00Outperform
    Mizuho
    2/3/2025$85.00 → $115.00Neutral → Buy
    Redburn Atlantic
    1/16/2025$86.00 → $104.00Neutral → Outperform
    Robert W. Baird
    7/26/2024$161.00 → $80.00Outperform → Neutral
    Robert W. Baird
    7/26/2024$145.00 → $75.00Overweight → Neutral
    JP Morgan
    5/30/2024$130.00Neutral
    Redburn Atlantic
    More analyst ratings

    $DXCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Truist initiated coverage on Dexcom with a new price target

      Truist initiated coverage of Dexcom with a rating of Buy and set a new price target of $102.00

      6/16/25 7:46:45 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Goldman initiated coverage on Dexcom with a new price target

      Goldman initiated coverage of Dexcom with a rating of Buy and set a new price target of $104.00

      5/30/25 8:41:14 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Mizuho initiated coverage on Dexcom with a new price target

      Mizuho initiated coverage of Dexcom with a rating of Outperform and set a new price target of $85.00

      4/10/25 12:40:59 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

      Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

      7/17/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Artificial Intelligence Revolutionizing Early Detection of Diabetic Retinopathy Creating a Multi-Billion Dollar Revenue Opportunity

      MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies.  AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often devel

      7/15/25 8:45:00 AM ET
      $ABT
      $DXCM
      $IRTC
      $TNDM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

      7/1/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    SEC Filings

    See more
    • SEC Form SD filed by DexCom Inc.

      SD - DEXCOM INC (0001093557) (Filer)

      5/29/25 4:35:26 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • DexCom Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - DEXCOM INC (0001093557) (Filer)

      5/13/25 8:31:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Amendment: DexCom Inc. filed SEC Form 8-K: Leadership Update

      8-K/A - DEXCOM INC (0001093557) (Filer)

      5/9/25 4:20:31 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Foletta Mark G sold $234,217 worth of shares (2,750 units at $85.17) (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      7/17/25 4:08:36 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • EVP, Chief Legal Officer Brown Michael Jon sold $43,015 worth of shares (500 units at $86.03), decreasing direct ownership by 0.53% to 94,602 units (SEC Form 4)

      4 - DEXCOM INC (0001093557) (Issuer)

      7/17/25 4:03:07 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Amendment: Director Gala Renee D was granted 1,161 shares, increasing direct ownership by 20% to 6,881 units (SEC Form 4)

      4/A - DEXCOM INC (0001093557) (Issuer)

      7/7/25 4:15:09 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Unveils Season 4 Roster for Game-Changing NIL Program at Signing Day Camp Hosted by Mark Andrews

      Dexcom's first-of-its-kind NIL program welcomes 13 new athletes and eight returning team members, including San Diego State University basketball standout Miles Byrd and Alabama A&M University's Shelomi Sanders The trailblazing program empowers college athletes with Type 1 diabetes to break barriers in sports and inspire their communities, as showcased at the Dexcom U Signing Day Camp, a new addition to the program, earlier this month DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the launch of the fourth season of Dexcom U, the company's one-of-a-kind NIL (Name, Image and Likeness) program exclusively for college athletes with diabetes. This pr

      7/17/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Launches First Nationwide Search for College Athletes With Diabetes to Join Season Four of Dexcom U

      Dexcom's first-of-its-kind NIL program is accepting nominations for passionate and inspiring college athletes with diabetes for its 2025 roster now through May 23. Selected athletes will be invited to the Dexcom U Signing Day Camp this summer, hosted by Dexcom Warrior and Baltimore Ravens tight end Mark Andrews. DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program exclusively for college athletes with diabetes – for an expanded fourth season, including the first-ever nationwide open call for passionate and inspiring college athletes to join its roster. This press release features

      4/22/25 8:00:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations

    $DXCM
    Financials

    Live finance-specific insights

    See more
    • Dexcom Schedules Second Quarter 2025 Earnings Release and Conference Call for July 30, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Management will hold a conference call to review the company's second quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the

      7/1/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Reports First Quarter 2025 Financial Results and Announces $750 Million Share Repurchase Program

      DexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended March 31, 2025. First Quarter 2025 Financial Highlights: Revenue grew 12% year-over-year to $1.036 billion on a reported basis and 14% year-over-year on an organic1 basis. U.S. revenue grew 15% and international revenue grew 7% on a reported basis and 12% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $133.7 million or 12.9% of revenue, an increase of 190 basis points compared to the first quarter of 2024. Non-GAAP operating income* of $143.1 million or 13.8% of reported revenue, a decrease of 140 basis points compared to the first quarter of 2024. First Qu

      5/1/25 4:02:00 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • Dexcom Schedules First Quarter 2025 Earnings Release and Conference Call for May 1, 2025 at 4:30 p.m. Eastern Time.

      DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 1, 2025. Management will hold a conference call to review the company's first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference. To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the start

      4/3/25 8:30:00 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care

    $DXCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/13/24 5:02:33 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/23 11:16:37 AM ET
      $DXCM
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by DexCom Inc. (Amendment)

      SC 13G/A - DEXCOM INC (0001093557) (Subject)

      2/9/22 3:43:37 PM ET
      $DXCM
      Medical/Dental Instruments
      Health Care